Serum LINE-1 hypomethylation as a potential prognostic marker for hepatocellular carcinoma

被引：102

作者：

Tangkijvanich, Pisit

Hourpai, Nusara

Rattanatanyong, Prakasit

Wisedopas, Naruemon

Mahachai, Varocha

Mutirangura, Apiwat ^{[1
]}

机构：

[1] Chulalongkorn Univ, Fac Med, Dept Anat, Mol Biol & Genet Canc Dev Res Unit, Bangkok 10330, Thailand

[2] Chulalongkorn Univ, Fac Med, Dept Biochem, Bangkok 10330, Thailand

[3] Chulalongkorn Univ, Fac Med, Dept Pathol, Bangkok 10330, Thailand

[4] Chulalongkorn Univ, Fac Med, Dept Med, Bangkok 10330, Thailand

来源：

CLINICA CHIMICA ACTA | 2007年 / 379卷 / 1-2期

关键词：

global hypomethylation; prognostic marker; hepatocellular carcinoma; COBRA LINE-1; hepatoma;

D O I：

10.1016/j.cca.2006.12.029

中图分类号：

R446 [实验室诊断]; R-33 [实验医学、医学实验];

学科分类号：

1001 ;

摘要：

Background: We investigated the clinical implications of global hypomethylation, one of the most consistent epigenetic changes in cancer, in the sera of patients with hepatocellular carcinoma (HCC). Methods: Combined bisulfite restriction analysis PCR was used to assess the methylation status of LINE-1 repetitive sequences in genomic DNA derived from sera of 85 patients with HCC, 73 patients with cirrhosis, 20 healthy carriers of hepatitis B virus (HBV) and 30 healthy controls. Results: Serum genome hypomethylation, the percentage of unmethylated LINE-1, was significantly increased in patients with HCC (P<0.001). The levels of serum LINE-1 hypomethylation at initial presentation correlated significantly with the presence of HBsAg, large tumor sizes, and advanced tumor stages classified by the CLIP score. Multivariate analyses showed that serum LINE-1 hypomethylation was a significant and independent prognostic factor of overall survival. Conclusion: Serum LINE-1 hypomethylation may serve as a prognostic marker for patients with HCC. (c) 2007 Elsevier B.V. All rights reserved.

引用

页码：127 / 133

页数：7